Project Details

Description

DESCRIPTION (provided by applicant): Central obesity, especially visceral obesity, is associated with higher risk for metabolic disease such as Type 2 diabetes. Glucocorticoids (GCs) are powerful regulators of adipose tissue function that modulate fat storage and release, regulate the production of adipokines, and suppress inflammation. GCs promote the preferential accumulation of visceral (e.g. Omental (Om)) adipose tissue, and also increase abdominal subcutaneous (Abdsc) adipose tissue. To elucidate mechanisms by which GCs regulate fat distribution and function of human adipose tissues, we tested its long-term effects using an organ culture system. The results indicated that GCs regulate ~30% of all genes, and that the dose-dependent and magnitude of the response was highly depot dependent. In addition to genes that regulate metabolic pathways, GCs caused clear changes in the expression of genes in the transforming growth factor beta (TGFß) pathway. The TGFß superfamily includes many secreted factors, including TGFb1 and 3, activin A (INHBA) that are known to regulate adipogenesis. This pathway was of interest because the ability to recruit new adipocytes from adipose stem cells (ASCs) within the tissues prevents excessive hypertrophy of existing adipocytes, and thereby preserves the normal metabolic and endocrine functions of the adipose tissues that are essential for metabolic health. Paradoxically, compared to Abdsc ASCs, Om ASCs differentiate poorly. New preliminary data show that expression of anti-adipogenic factors including INHBA is higher in Om. GCs shifted the balance to favor adipogenesis, but Om was less sensitive to these effects. Consistent with this model, net TGFß pathway signaling (indicated by the activation of SMAD2) was increased in Om ASCs, in proportional to differentiation degree under standard conditions, and conditioned media from Om adipose tissue or ASC inhibited differentiation of Abdsc ASCs. The goal of this proposal is elucidate the molecular and cellular mechanisms that regulate depot-dependent adipose tissue growth and metabolism. We will address three Specific Aims: 1) To determine the importance of TGFß pathway in mediating depot differences in adipogenesis, 2) To test the hypothesis that GC-TGFß crosstalk modulates depot-dependent gene expression, adipogenesis and adipocyte function, and 3) To elucidate mechanisms by which mild, chronic hypercortisolemia modulates human adipose tissue function in vivo. Collectively, this work may lead to the identification of therapeutic targets downstream o GR to treat or prevent abdominal obesity and its metabolic consequences.
StatusFinished
Effective start/end date1/06/0931/03/20

Funding

  • National Institute of Diabetes and Digestive and Kidney Diseases: $359,434.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $381,375.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $381,375.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $359,434.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $356,164.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $346,854.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $35,336.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $401,544.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $383,994.00
  • National Institute of Diabetes and Digestive and Kidney Diseases: $404,000.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.